Last reviewed · How we verify
APRETUDE
At a glance
| Generic name | APRETUDE |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs (PHASE4)
- Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (PHASE4)
- A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories (PHASE4)
- Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) (PHASE3)
- A Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-Volume PrEP Site in the United States (PHASE4)
- Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
- Implementation and Delivery of Cabotegravir Long Acting Injection for PrEP in a Community Pharmacy Setting.
- Parrying the Pitfalls of PrEP: Project PEACH (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |